Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 3.67 · gapped above the open, then crossed back over prior close. High/low 4.28 at 7:00 am ET, 3.67 at 4:00 pm ET.
EyePoint, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Laboratory Analytical Instruments
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Under an Asset Purchase Agreement with Aerpio Pharmaceuticals Inc. (Aerpio) in 2021, we acquired all right title and interest in and to certain U.S. and ex-U.S. patents and applications relating to certain TIE-2 activating molecules, including razuprotafib.”
FILING10-K0001193125-26-093917cik 0001314102
“The development and commercialization of our lead product candidate, DURAVYU, is dependent on intellectual property we license from Equinox Science and active pharmaceutical ingredient (API) supply of vorolanib.”
FILING10-K0001193125-26-093917cik 0001314102
“We source the API from Farmabios, needles from a third party supplier and various other raw materials and components for YUTIQ ® from additional third-party vendors.”
FILING10-K0001193125-26-093917cik 0001314102
“We originally licensed our Durasert ® proprietary insert technology to ANI for use in ILUVIEN for the treatment of all ocular diseases (excluding uveitis).”
FILING10-K0001193125-26-093917cik 0001314102
“Under the Betta License Agreement, the Company granted to Betta an exclusive, sublicensable, royalty-bearing license under certain of the Company's intellectual property to develop, use (but not make or have made), sell, offer for sale, and import the Company's product candidate, DURAVYU, an investigational sustained delivery intravitreal anti-VEGF treatment that combines a bioerodible formulation of the Company's proprietary sustained-release technology with the compound vorolanib (the Licensed Product), in the field of ophthalmology (the Betta Field) in the Greater Area of China, including China, the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan (the Betta Territory).”
FILING10-K0001193125-26-093917cik 0001314102
“We have licensed clinical development, regulatory, reimbursement and distribution rights to YUTIQ ® to Ocumension for Mainland China, Hong Kong, Macau, Taiwan, South Korea, and other jurisdictions across Southeast Asia.”
FILING10-K0001193125-26-093917cik 0001314102
“We license one utility patent right relating to the YUTIQ injector from EyePoint Pharmaceuticals US, Inc. (f/k/a pSivida US, Inc. or "EyePoint").”
FILING10-K0001023024-26-000014cik 0001023024disclosed by ANIP
Watchlist prices, news filtered to it, and its next report on your desk.
EyePoint, Inc. has 3 disclosed suppliers and 4 disclosed customers. Each one is named in an SEC filing, either EyePoint, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
EYPT (EyePoint, Inc.) has 3 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ANIP +1.58%, in healthcare.